Therefore, the use of CBMC combined with S-1 monotherapy in the treatment of advanced colorectal cancer has better efficacy, can significantly improve the quality of life of patients and reduce the levels of CEA, VEGF, and CA199, and is worthy of clinical popularization and application (124). The gene discussed is VEGFA; the disease is colorectal cancer.